Low-Dose Ketamine in Emergency Psychiatry: Acute Management Protocols

Introduction: The Need for Rapid-Acting Interventions in Psychiatric Emergencies

Psychiatric emergencies -- encompassing acute suicidal ideation with imminent risk, severe agitation, and acute depressive crises -- represent clinical scenarios in which the latency of conventional psychotropic medications creates a critical treatment gap. Low-dose ketamine in emergency psychiatry has attracted growing attention as a potential bridge intervention capable of producing rapid symptomatic improvement within minutes to hours, potentially enabling safer disposition and reducing the need for prolonged psychiatric holds (Murrough et al., 2015). The emergency department (ED) setting presents unique opportunities and challenges for ketamine deployment: existing familiarity with ketamine for procedural sedation, infrastructure for medical monitoring, and the clinical urgency that may justify earlier intervention than outpatient settings.

The epidemiological context underscores the need for emergency-setting rapid interventions. Emergency department visits for suicidal ideation and self-harm have increased significantly over the past decade, with ED psychiatric boarding -- patients awaiting inpatient psychiatric beds -- averaging 8-12 hours and sometimes extending to days (Nicks and Manthey, 2012). During this waiting period, patients with acute suicidality receive limited pharmacological intervention beyond sedation, as conventional antidepressants require weeks for therapeutic effect. Ketamine's rapid anti-suicidal properties could transform this critical waiting period from passive observation to active treatment.

Acute Suicidal Ideation Management

Evidence for Rapid Anti-Suicidal Effects

The anti-suicidal effects of ketamine represent perhaps its most clinically impactful property for emergency settings. A meta-analysis by Wilkinson and colleagues (2018), published in The American Journal of Psychiatry, synthesized data from 10 studies examining ketamine's effects on suicidal ideation, finding significant and rapid reduction in suicidality within 4-24 hours of administration. Effect sizes for suicidal ideation reduction were large (Cohen's d approximately 0.8-1.0) and clinically meaningful, with many patients transitioning from active suicidal ideation with plan to passive ideation or no ideation within hours.

Grunebaum and colleagues (2018), in a randomized controlled trial published in The American Journal of Psychiatry, compared a single ketamine infusion (0.5 mg/kg over 40 minutes) with midazolam active placebo in 80 patients with clinically significant suicidal ideation. Ketamine produced significantly greater reduction in Scale for Suicide Ideation (SSI) scores at 24 hours, with 55% of ketamine-treated patients achieving clinically significant improvement compared with 30% receiving midazolam. Importantly, the anti-suicidal effect was partially independent of the antidepressant effect, suggesting a mechanistically distinct action on suicide-specific neural circuitry.

Emergency Department Implementation

Several ED-based pilot studies have examined the feasibility and safety of sub-dissociative ketamine for acute suicidal presentations. Domany and colleagues (2020), published in The Journal of Clinical Psychiatry, conducted a randomized controlled trial of intravenous ketamine (0.2 mg/kg bolus) versus saline placebo in 18 ED patients presenting with suicidal ideation. Ketamine produced significant reduction in suicidal ideation within 90 minutes, with effects sustained at 4 hours. The lower dose (0.2 mg/kg bolus rather than the standard 0.5 mg/kg over 40 minutes) was selected for ED feasibility, demonstrating that rapid anti-suicidal effects may be achievable at doses below the standard antidepressant protocol.

Kashani and colleagues (2014) reported on intranasal ketamine (50 mg) administered to suicidal ED patients, observing rapid reduction in suicidality scores within 40 minutes. The intranasal route offers practical advantages in the ED setting -- no IV access required, rapid administration, and established familiarity from analgesic protocols.

Acute Agitation Management

Sub-Dissociative Doses for Psychiatric Agitation

Ketamine at sub-dissociative doses (0.25-0.5 mg/kg IV or 2-4 mg/kg IM) has been studied as an agent for managing acute psychiatric agitation -- a common ED presentation that encompasses a range of etiologies including psychotic disorders, substance intoxication, and severe anxiety states. Barbic and colleagues (2021), in a systematic review published in Academic Emergency Medicine, examined 14 studies of ketamine for ED agitation, finding rapid onset of effect (typically within 5-15 minutes for IM administration) and good overall efficacy.

However, the use of ketamine for agitation management in psychiatric patients raises specific concerns. Higher dissociative doses (4-5 mg/kg IM), commonly used for chemical restraint of violent patients, produce a qualitatively different experience from the sub-anesthetic psychiatric doses and carry different risk profiles. The distinction between sub-dissociative ketamine for therapeutic purposes and dissociative ketamine for behavioral control should be clearly maintained in clinical protocols and documentation.

Comparison with Standard Agents

Standard pharmacological management of acute agitation in the ED involves intramuscular haloperidol (often combined with lorazepam and diphenhydramine -- the "B52" cocktail), intramuscular olanzapine, or intramuscular ziprasidone. Ketamine offers potential advantages in specific scenarios:

• Faster onset: Intramuscular ketamine produces sedation within 5 minutes, versus 15-30 minutes for haloperidol
• Analgesic properties: Beneficial when agitation coexists with pain (trauma, self-injury)
• Respiratory safety: Ketamine preserves airway reflexes and respiratory drive, in contrast to benzodiazepines which carry respiratory depression risk

Disadvantages include sympathomimetic cardiovascular effects, the potential for emergence reactions, and concerns about exacerbating psychotic symptoms in patients with primary psychotic disorders.

Emergency Protocol Development

Triage and Patient Selection

ED implementation requires clear triage criteria for identifying appropriate ketamine candidates:

Inclusion considerations:

• Active suicidal ideation with intent or plan (C-SSRS ideation intensity greater than or equal to 4)
• Severe acute depressive episode with functional incapacitation
• Treatment-resistant depression presenting in crisis
• Failed de-escalation with standard interventions

Exclusion considerations:

• Active psychotic symptoms (hallucinations, delusions)
• Uncontrolled hypertension (SBP greater than 180 mmHg)
• Known hypersensitivity to ketamine
• Active intoxication with substances that may interact adversely (PCP, other dissociatives)
• Pregnancy (relative exclusion; severity-dependent)

Administration Protocols

Several ED-adapted ketamine protocols have been proposed:

Rapid IV protocol:

• Ketamine 0.5 mg/kg IV over 40 minutes (standard antidepressant protocol)
• Requires dedicated IV access, infusion pump, and 2-3 hours of monitoring space
• Most closely replicates the evidence base from research trials

Sub-dissociative IV bolus:

• Ketamine 0.1-0.3 mg/kg IV push over 1-2 minutes
• Rapid administration suitable for time-pressured ED environments
• May produce less sustained anti-suicidal effect than the standard 40-minute infusion
• Familiar to emergency physicians from analgesic ketamine protocols

Intranasal protocol:

• Ketamine 50-100 mg via intranasal atomizer
• No IV access required; can be administered during triage
• Bioavailability approximately 25-50%; effective dose range under investigation
• Particularly practical for pediatric/adolescent populations

Intramuscular protocol:

• Ketamine 0.5-1.0 mg/kg IM
• Useful when IV access is not immediately available
• Peak effect in 15-20 minutes; somewhat less predictable pharmacokinetics than IV

Monitoring and Disposition

Post-administration monitoring in the ED should include:

• Vital signs every 15 minutes for the first hour, then every 30 minutes
• Continuous pulse oximetry
• Dissociative symptom assessment (abbreviated CADSS or clinical observation)
• Suicidality re-assessment (C-SSRS) at 2 hours and at disposition
• Observation for a minimum of 2 hours post-administration

Disposition decisions following emergency ketamine administration should incorporate the degree of suicidality reduction, the patient's clinical trajectory, available outpatient follow-up resources, and standard psychiatric emergency disposition criteria. Ketamine is not a substitute for comprehensive psychiatric evaluation and disposition planning -- it is an adjunctive intervention that may facilitate safer and more effective disposition.

Integration with Emergency Psychiatric Workflows

Psychiatric Consultation Model

In most ED settings, ketamine administration for psychiatric indications should involve psychiatric consultation. The emergency physician provides medical clearance and hemodynamic monitoring capability, while the psychiatrist assesses diagnostic indication, contraindications, and treatment appropriateness. This collaborative model leverages the expertise of both specialties.

Bridging to Outpatient Care

Emergency ketamine administration is most effective when integrated with a clear plan for outpatient follow-up. Patients who respond to emergency ketamine should be connected with outpatient ketamine treatment providers, crisis follow-up services, and ongoing psychiatric care within 24-72 hours of ED discharge. Without this continuity of care, the transient nature of ketamine's effect may lead to recurrent crisis presentation.

Special Populations in the Emergency Setting

Adolescents

Adolescent suicidal presentations in the ED represent a particularly compelling potential application for ketamine, given the epidemic of adolescent suicide and the limited pharmacological options for acute intervention in this age group. The evidence base for ketamine in adolescent emergency presentations is limited to case reports and small series (Zarrinnegar et al., 2019), but the clinical need is substantial. Age-appropriate dosing, consent considerations, and enhanced monitoring are essential.

Substance-Intoxicated Patients

Patients presenting with suicidal ideation in the context of acute substance intoxication require careful consideration. Alcohol or benzodiazepine intoxication may alter ketamine's pharmacological effects and increase respiratory risk. Stimulant intoxication may amplify ketamine's sympathomimetic cardiovascular effects. The safest approach for intoxicated patients is medical stabilization and sobering before ketamine administration, though the severity of suicidal risk may occasionally necessitate concurrent intervention.

Medically Comorbid Patients

ED psychiatric presentations frequently involve medical comorbidity. Ketamine's hemodynamic effects require consideration in the context of concurrent medical conditions. The advantage of ED-based administration is the immediate availability of medical monitoring, resuscitation equipment, and emergency intervention capability -- providing a higher safety margin than outpatient ketamine clinics for medically complex patients.

Barriers to Implementation

Regulatory and Institutional Barriers

Implementation of emergency ketamine for psychiatric indications faces several barriers: institutional hesitancy regarding off-label controlled substance use, absence of standardized ED protocols, limited psychiatry-emergency medicine collaborative frameworks, and concerns about potential for regulatory scrutiny.

Workforce and Training

Emergency physicians have extensive experience with ketamine for procedural sedation and analgesia but may be less familiar with sub-anesthetic psychiatric dosing protocols and the assessment tools used to measure psychiatric outcomes. Targeted training programs addressing psychiatric indication assessment, dosing protocols, outcome measurement, and disposition planning are needed to support ED implementation.

Economic Considerations

The cost of ketamine itself is minimal (generic racemic ketamine costs approximately $5-10 per dose). However, the monitoring time (2-3 hours of ED bed utilization), nursing support, and physician oversight represent opportunity costs in resource-constrained ED environments. Health economic analyses comparing the cost of ED ketamine administration against the cost of prolonged psychiatric boarding, repeat ED visits, and inpatient hospitalization are needed to establish the economic case for implementation (Sinyor et al., 2020).

Conclusion

Low-dose ketamine in emergency psychiatry represents a paradigm with the potential to transform the acute management of suicidal crises and severe depressive presentations. The evidence for rapid anti-suicidal effects is compelling, and the ED setting provides the medical infrastructure for safe administration and monitoring. Implementation requires the development of standardized protocols adapted to ED workflows, collaborative frameworks between emergency medicine and psychiatry, clear patient selection criteria, and integration with outpatient follow-up pathways. As clinical experience and evidence accumulate, emergency ketamine may become a standard component of the psychiatric crisis intervention toolkit.

References

• PubMed: Ketamine for Acute Suicidality in the Emergency Department: A Systematic Review — Systematic review of prospective studies evaluating ketamine for acute suicidal ideation in emergency department settings
• PubMed: Ketamine for Acute Suicidal Ideation in the ED: A Proof-of-Concept Trial — Randomized double-blind placebo-controlled trial of intravenous ketamine for rapid reduction of suicidal ideation in ED patients
• NIMH: Suicide Prevention — National Institute of Mental Health resources on suicide prevention research and crisis intervention strategies
• 988 Suicide and Crisis Lifeline — National crisis intervention service providing 24/7 support for individuals in suicidal crisis